Skip to content
For US Healthcare Professionals Patient Site
Picture of LEMTRADA patient Donnie. Picture of LEMTRADA patient Donnie.
Donnie
48
Winchester, KY
married, father of 2, former high school football player
“I was worried about disease progression and the possible impact that could have on my family.”

DISEASE HISTORY

15 Years

since RMS diagnosis

PATIENT BACKGROUND

RMS Risk Factors

male, severe disability progression

RMS TREATMENT HISTORY

4 prior DMTs:
2 injectables,
1 oral therapy, and
1 infusion treatment

WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

I was experiencing multiple relapses every year and my disability continued to progress. My primary concern was how my family could be affected. It was a turning point.

WHY LEMTRADA?

First, I liked that it showed an effect on relapse rate and disability progression. Also, that it would be 5 days of infusion the first year and 3 days one year later. And I knew I could adhere to the monitoring requirements.

HOW DID YOU HANDLE ANY CONCERNS ABOUT SAFETY AND SUPPORT?

The monthly monitoring seemed like a big commitment, but my doctor said it was necessary to help detect serious side effects early. Overall, I felt I would be supported throughout my LEMTRADA treatment by my doctor and my healthcare team. Having a team behind me helped a lot!

WHAT WOULD YOU TELL SOMEONE CONSIDERING SWITCHING?

I’m glad I made the switch and didn’t give up on finding the right treatment for me. Listen to your doctor, and work with them to find a treatment plan that works for you.

Are your patients interested in learning
more about LEMTRADA?

Download the full patient resource

INDICATION

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

CONTRAINDICATIONS

LEMTRADA is contraindicated in patients:

WARNINGS AND PRECAUTIONS

Most Common Adverse Reactions

In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

Use in Specific Populations

Physicians are encouraged to report pregnancies by calling 1-800-745-4447, option 2. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING.

Indication

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

  • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum
Alternate Text